Galectin-3 in Papillary Thyroid Carcinoma

NCT ID: NCT05699590

Last Updated: 2023-01-27

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 60 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-03-31
• Study Completion Date: 2023-06-30

Brief Summary

Thyroid cancer is a common head and neck malignancy. It is the most common endocrine tumor in the body accounting for 1% of all cancers worldwide. The incidence of thyroid cancer varies worldwide. Most countries have reported an upward trend in its incidence.

Thyroid cancer encompass the most common well-differentiated papillary carcinoma (80% of all thyroid cancers) and follicular carcinoma (15%), as well as poorly differentiated carcinoma (< 1%) and anaplastic carcinoma (< 2%).

Papillary thyroid carcinomas (PTCs) are the most commonly encountered thyroid malignancies. The diagnosis of PTC is based on the special nuclear features such as overlapping of nuclei, intranuclear inclusions, optical clearing, anisonucleosis and nuclear grooves. However, it is often difficult to differentiate PTC from benign papillary thyroid hyperplasia . As differentiation between benign or malignant thyroid lesions has clinical, therapeutic, and prognostic significance, it is necessary to make accurate diagnosis by using biomarkers.

Recently, a large number of immunohistochemical (IHC) markers have been studied to assist in differentiating non-neoplastic lesions from malignant thyroid lesions. CK19, galectin-3, TG, Ki67, BRAF, calcitonin, HBME-1, TTF-1, and RET are some of the examples of these IHC markers.

Galectin-3 is a 31-kDa β-galactoside binding lectin. It has been shown to be expressed by several types of non-neoplastic and neoplastic cells, and it is involved in cell-cell adhesion and in cell-matrix interactions.

Conditions

Galactin 3-thyroid Carcinoma

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: RETROSPECTIVE

Eligibility Criteria

Inclusion Criteria

1. Thyroidectomy specimens both hemithyroidectomy and total thyroidectomy.

2. All the studied cases include sufficient materials for the immunohistochemical study.

3. Complete clinical data

Exclusion Criteria

1. Patients with recurrence of the primary tumor.

2. Patients with a history of preoperative chemotherapy and/or radiotherapy.

3. Insufficient or tiny tissue biopsies

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sohag University

OTHER

Sponsor Role: lead

Responsible Party

Amira Ahmed Abdelnaby

Lecturer of pathology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Amira Ahmed Abdelnaby, Lecturer

Role: PRINCIPAL_INVESTIGATOR

Pathology department, Faculty of medicine ,Sohag university

Central Contacts

Amira A Abdelnaby, Lecturer

Role: CONTACT

ameraabdelnaby55@gmail.com

01002097612

Other Identifiers

Soh-Med-23-1-35

Identifier Type: -

Identifier Source: org_study_id